



SYNTHESIS, CHARACTERIZATION AND ANTIFUNGAL POTENTIAL OF 1-AMINOMETHYL-3-{4'-(4''-NITROBENZYLOXY) - BENZOYLHYDRAZONO} -5-METHYLINDOLIN-2-ONES

Nisheeth Rastogi¹, Padam Kant² and Darwin Anil Harrison¹

¹Dr. W. E. Bauer Research Laboratory, Department of Chemistry, Lucknow Christian Post-Graduate College, Lucknow-226018 (U.P.), India.

²Department of Chemistry, University of Lucknow, Lucknow-226007 (U.P.), India.

ABSTRACT

A new series of 1-aminomethyl- 3-{4'-(4''-nitrobenzyloxy)benzoylhydrazono}-5-methylindolin-2-ones (Mannich bases) have been synthesized and screened for their antifungal potential against human pathogenic fungi. The structures of the compounds have been established with the help of elemental analysis and spectral data (IR, ¹H NMR and Mass).

Keywords: Indolin-2,3-dione, Schiff base, Mannich base, aminomethylation, antifungal activity.

Introduction

Indolin-2,3-diones and their derivatives possess wide variety of biological activities viz., anticonvulsant¹, antitubercular², cytotoxic³, antimicrobial^{4,5}, antileishmanial⁶, antifertility⁷, analgesic⁸, antiinflammatory⁹ and enzyme inhibitory¹⁰. Recently number of articles¹¹⁻²⁶ have been published on the chemistry, biological potential and toxicity of indolin-2, 3-diones. In the light of biological activity profile of indolin-2, 3-diones and in continuation of our work²⁷⁻³⁰ on biologically active heterocycles, it was considered of interest to synthesize a new series of 1-aminomethyl -3-{4'-(4''-nitrobenzyloxy)benzoylhydrazono}- 5-methylindolin-2-ones (Mannich bases).

4-(4'-Nitrobenzyloxy)-benzoylhydrazine **2** was prepared by hydrazinolysis of methyl 4-(4'-nitrobenzyloxy)-benzoate **1** which in turn was obtained by O-benylation of methyl 4-hydroxybenzoate with 4-nitrobenzyl bromide. Benzoylhydrazine **2** on condensation with 5-methylindolin-2, 3-diones in equimolar proportion, gave 3-{4'-(4''-nitrobenzyloxy)-

benzoylhydrazono}-5-methylindolin-2-ones (Schiff bases) **3-8**. Compound **3** on being subjected to aminomethylation with secondary amines in the presence of formaldehyde, gave 1-aminomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-ones (Mannich bases) **9-17** (Scheme I).

Antifungal activity

All the compounds **3-17** were screened for their *in-vitro* antifungal potential against human pathogenic fungi *Candida albicans* (CA), *Cryptococcus neoformans* (CN), *Trichophyton mentagrophytes* (TM) and *Aspergillus fumigatus* (AF) using tube dilution method^{31,32} at a maximum concentration of 100 µg/mL in DMSO. The spore suspension of 10⁵ spores/mL was used for this purpose. The drug dilutions were made serially. The test was performed at 29°C and Minimum Inhibitory Concentration (MIC) in µg/mL was recorded by visual observation after 24-72 h incubation. Suitable controls: broth control (without infection), growth control (with infection), solvent DMSO, drug controls (all test compounds) and ketoconazole (as standard drug) were set under identical conditions. The last tube with no apparent growth of organism represented the MIC of compound. Antifungal activity data are presented in **Table I**.

Table 1

Minimum Inhibitory Concentration, MIC (µg/mL) of compounds against Fungi

Compd	<i>Candida albicans</i> (CA)	<i>Cryptococcus neoformans</i> (CN)	<i>Trichophyton mentagrophytes</i> (TM)	<i>Aspergillus fumigatus</i> (AF)
3	>100	>100	>100	>100
4	25	25	6.25	12.5
5	50	6.25	12.5	12.5
6	25	3.12	6.25	12.5
7	>100	>100	12.5	12.5
8	50	>100	12.5	12.5
9	>100	>100	25	25
10	12.5	50	6.25	12.5
11	12.5	50	6.25	12.5
12	>100	25	25	25
13	>100	>100	50	25
14	>100	>100	12.5	12.5
15	>100	>100	25	12.5
16	50	25	12.5	50
17	50	12.5	12.5	50
Ketokonazole (Standard drug)	0.39	0.78	3.12	6.25

Experimental

The melting points were determined in open capillary tubes in sulphuric acid bath and are uncorrected. IR spectra were recorded in KBr on a Perkin Elmer RX1 spectrophotometer and ^1H NMR on Bruker Avance 400 spectrometer. $\text{CDCl}_3/\text{DMSO}-d_6$ were used as solvent and TMS as internal reference. Chemical shifts are expressed in δ (ppm). Mass spectra were recorded on Shimadzu GC-MS Q P2010 instrument. Elemental analysis data were obtained on Carlo Erba 1108 analyser. Homogeneity of the compounds were checked by TLC silica gel G plates and spots were located by exposure to iodine vapours.

Methyl 4-(4'-nitrobenzyloxy)-benzoate, **1**

A mixture of methyl 4-hydroxybenzoate (0.045 mol), 4-nitrobenzyl bromide (0.045 mol) and anhyd. K_2CO_3 (7.1 g) in acetone (70 mL) was refluxed for 9-10 hr. Excess of solvent was distilled off and the contents were poured into cold water. The solid so obtained was filtered, washed with water, dried and purified by recrystallization from 1-propanol. Yield 78%, m.p. 182-84°C; IR (KBr): 1708 (CO), 1529, 1350 (NO_2), 1261 cm^{-1} ($-\text{CH}_2\text{O}-$).

4-(4'-Nitrobenzyloxy)-benzoylhydrazine, **2**

Compound **1** (0.01 mol) and hydrazine hydrate (99%, 0.01 mol) in 1-propanol (100 mL) were refluxed for 24 hr. Excess of solvent was distilled off and the contents were poured into water. The solid thus obtained was filtered, washed with water, dried and purified by recrystallization from 1-propanol. Yield 84%, m.p. 202-04°C; IR (KBr): 3315, 3179 (NHNH_2), 1659 (CONH), 1527, 1350 (NO_2), 1255 cm^{-1} ($-\text{CH}_2\text{O}-$).

3-{4'-(4''-Nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin -2-one, **3**

A mixture of 4-(4'-nitrobenzyloxy)-benzoylhydrazine **2** (0.01 mol) and 5-methylindolin-2,3-dione (0.01 mol) in ethanol (50 mL) containing 2-3 drops of glacial acetic acid was refluxed for 1 hr and left overnight at RT. The separated solid was filtered and washed with methanol. Yield 76%, m.p. >280°C; IR (cm^{-1}): 3480, 3170 (NH), 1691(CO), 1528, 1345 (NO_2), 1254 ($-\text{CH}_2\text{O}-$); MS (m/z): 430 (M^+). (Found: C, 64.10; H, 4.10; N, 12.96. Calcd. for $\text{C}_{23}\text{H}_{18}\text{N}_4\text{O}_5$: C, 64.18; H, 4.22; N, 13.02%).

Compounds **4-8** were synthesised by similar methods using 1-Methyl, ethyl, benzyl, acetyl and hydroxymethyl-5-methylindolin-2, 3-diones.

1-Methyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 4

Yield 86%; m.p.260 (d)°C; ¹H NMR (DMSO-*d*₆) δppm: 2.54 (3H, s, ArMe), 2.63 (3H, s, NMe), 5.25 (2H, s -CH₂O-), 6.96-8.02 (11H, m, Ar-H), 13.98 (1H, s, CONH), MS m/z: 444 (M⁺). (Found: C, 64.76; H, 4.43; N, 12.66. Calcd. for C₂₄H₂₀N₄O₅: C, 64.86; H, 4.50; N, 12.61%).

1-Ethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 5

Yield 73 %; m.p 200-02°C; ¹H NMR (DMSO-*d*₆) δppm: 1.12-1.19 (3H, t, NCH₂CH₃), 2.56 (3H, s, ArMe), 2.86-3.13 (2H, q, NCH₂CH₃), 5.25 (2H, s, -CH₂O-), 6.88-8.12 (11H, m, Ar-H), 13.98 (1H, s, CONH), MS m/z: 458 (M⁺). (Found: C, 65.37; H, 4.77; N, 12.17. Calcd. for C₂₅H₂₂N₄O₅ : C, 65.49; H, 4.84; N, 12.22%).

1-Benzyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 6

Yield 67 %; m.p 218-20°C; ¹H NMR (DMSO-*d*₆) δppm: 2.56 (3H, s, ArMe), 4.92(2H, s, NCH₂Ph), 5.25 (2H, s, -CH₂O-), 6.96-8.11 (16H, m, Ar-H), 13.90 (1H, s, CONH), MS m/z: 520 (M⁺). (Found: C, 69.17; H, 4.60; N, 10.67. Calcd. for C₃₀H₂₄N₄O₅ : C, 69.22; H, 4.65; N, 10.76%).

1-Acetyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 7

Yield 66 %; m.p.220°C; ¹H NMR (DMSO-*d*₆) δppm: 2.32 (3H, s, COMe), 2.56 (3H, s, ArMe), 5.25 (2H, s, -CH₂O-), 6.91-8.02 (10H, m, Ar-H), 13.89 (1H, s, CONH), MS m/z: 472 (M⁺) (Found: C, 63.52; H, 4.23; N, 11.83. Calcd. for C₂₅H₂₀N₄O₆ : C, 63.56; H, 4.27; N, 11.86%);

1-Hydroxymethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 8

Yield 70 %; m.p >260°C; ¹H NMR (DMSO-*d*₆) δppm: 2.60 (3H, s, ArMe), 5.10 (2H, s, NCH₂OH), 5.25 (2H, s, -CH₂O-), 6.42 (1H, bs, NCH₂OH), 6.94-8.00 (10H, m, Ar-H), 13.87 (1H, s, CONH), MS m/z: 460 (M⁺). (Found: C, 62.57; H, 4.35; N, 12.13. Calcd. for C₂₄H₂₀N₄O₆ : C, 62.60; H, 4.38; N, 12.17%).

1-Morpholinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 9

To a suspension of **3** (0.005 mol) in DMF, formaldehyde (0.5mL, 37% aq. solution) and morpholine (0.005 mol) were added with vigorous stirring, and the reaction mixture was

warmed for 2 min on a water bath and left overnight at RT. The solid product thus obtained was filtered, washed with methanol, dried and purified by recrystallization from chloroform: pet.-ether (60-80°C) (1:1). Yield 74 %, m.p.212-14⁰C; IR (cm⁻¹): 3480 (NH), 2804 (>N-CH₂-N<), 1683 (CO), 1529, 1349 (NO₂), 1253 (-CH₂O-) 1157 (-CH₂-O-CH₂-); ¹H NMR (CDCl₃) δppm: 2.60 (3H, s, ArMe), 2.63-2.67 (4H, t, -CH₂-N-CH₂-), 3.69-3.72 (4H, t, -CH₂-O-CH₂-), 4.52 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 6.77-8.12 (11H, m, Ar-H), 13.77 (1H, s, CONH); MS m/z: 529(M⁺). (Found: C, 63.44; H, 5.04; N, 13.17. Calcd. for C₂₈H₂₇N₅O₆ : C, 63.51; H, 5.14; N, 13.23 %).

1-Piperidinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin -2-one, 10

Yield 68 %, m.p.212-14⁰C; IR (cm⁻¹): 3445 (NH), 2850 (>N-CH₂-N<), 1686 (CO), 1521, 1349 (NO₂), 1250 (-CH₂O-); ¹H NMR (CDCl₃): 1.42-1.59 (6H, m,-CH₂CH₂CH₂-), 2.56 (3H, s, ArMe), 2.58-2.61 (4H, t, -CH₂-N-CH₂-), 4.52(2H, s, >N-CH₂-N<), 5.25 (2H, s,-CH₂O-), 7.07-8.01 (11H, m, Ar-H), 13.87 (1H, s, CONH); MS m/z: 527 (M⁺). (Found: C, 65.92; H, 5.46; N, 13.18. Calcd. for C₂₉H₂₉N₅O₅ : C, 66.02; H, 5.54; N, 13.27 %).

1-Pyrrolidinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 11

Yield 68 %, m.p.200⁰C; IR (cm⁻¹): 3440 (NH), 2843 (>N-CH₂-N<), 1678 (CO), 1522, 1345 (NO₂), 1251 (-CH₂O-); ¹H NMR (CDCl₃): 1.35-1.42 (4H, m, -CH₂CH₂-), 2.33-2.46 (4H, t, -CH₂-N-CH₂-), 2.59 (3H, s, ArMe), 4.54 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.05-8.15 (11H, m, Ar-H), 13.83 (1H, s, CONH); MS m/z: 513 (M⁺). (Found: C, 65.40; H, 5.26; N, 13.57. Calcd. for C₂₈H₂₇N₅O₅ : C, 65.49; H, 5.30; N, 13.64 %).

1-N-Methylpiperazinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 12

Yield 69 %, m.p.218(d) ⁰C; ¹H NMR (CDCl₃): 1.87 (3H, s, N-Me), 2.33-2.39 (4H, t, -CH₂-N-CH₂-), 2.53 (3H, s, ArMe), 2.56-2.65 (4H, t, -CH₂-N(Me)-CH₂-), 4.55 (2H, s, >N-CH₂-N<), 5.25 (2H, s,-CH₂O-), 6.88-7.88 (11H, m, Ar-H), 14.00 (1H, s, CONH); MS m/z: 542 (M⁺). (Found: C, 64.08; H, 5.49; N, 15.47. Calcd. for C₂₉H₃₀N₆O₅ : C, 64.19; H, 5.57; N, 15.49 %).

1-N-Ethylpiperazinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 13

Yield 69 %, m.p.218(d) °C; ¹H NMR (CDCl₃): 1.87-1.92 (3H, t, -CH₂Me), 2.00-2.09 (2H, q, -CH₂Me), 2.33-2.39 (4H, t, -CH₂-N-CH₂-), 2.54 (3H, s, ArMe), 2.59-2.67 (4H, t, -CH₂-N(Et)-CH₂-), 4.58 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 6.88-7.99 (11H, m, Ar-H), 13.89 (1H, s, CONH); MS m/z: 556 (M⁺). (Found: C, 64.78; H, 5.68; N, 15.07. Calcd. for C₃₀H₃₂N₆O₅ : C, 64.73; H, 5.79; N, 15.10 %).

1-N-Phenylpiperazinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 14

Yield 60 %, m.p.214-16°C (d); IR (cm⁻¹): 3453 (NH), 2839 (>N-CH₂-N<), 1680 (CO), 1529, 1346 (NO₂), 1244(-CH₂O-); ¹H NMR (CDCl₃): 2.33-2.41(4H, t, -CH₂-N-CH₂-),2.56 (3H, s, ArMe), 2.60-2.69 (4H, t, -CH₂-N(Ph)-CH₂-), 4.55 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.04-8.28 (16H, m, Ar-H), 13.90 (1H, s, CONH); MS m/z: 604 (M⁺). (Found: C, 67.52; H, 5.26; N, 13.87. Calcd. for C₃₄H₃₂N₆O₅: C, 67.54; H, 5.33; N, 13.90 %).

1-N-Benzylpiperazinomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 15


Yield 55 %, m.p.186-88⁰ C; ¹H NMR (CDCl₃): 2.31-2.41 (4H, t, -CH₂-N-CH₂-), 2.56 (3H, s, ArMe), 2.62-2.71 (4H, t, -CH₂-N(CH₂Ph)-CH₂-), 4.49 (2H, s, CH₂Ph), 4.55 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.04-8.26 (16H, m, Ar-H), 13.93 (1H, s, CONH); MS m/z: 618 (M⁺). (Found: C, 67.82; H, 5.46; N, 13.53. Calcd. for C₃₅H₃₄N₆O₅ : C, 67.95; H, 5.54; N, 13.58 %).

1-Dimethylaminomethyl-3-{4'-(4''-nitrobenzyloxy)-benzoylhydrazono}-5-methylindolin-2-one, 16

Yield 48 %, m.p.140 °C; IR (cm⁻¹): 3427 (NH), 2832 (>N-CH₂-N<), 1699 (CO), 1523, 1348 (NO₂), 1258 (-CH₂O-); ¹H NMR (CDCl₃): 2.33 (6H, s, NMe₂), 2.63 (3H, s, ArMe), 4.27 (2H, s, >N-CH₂-N<), 5.26 (2H, s, -CH₂O-), 7.00-8.26 (11H, m, Ar-H), 13.98 (1H, s, CONH); MS m/z: 487 (M⁺). (Found: C, 64.00; H, 5.09; N, 14.30. Calcd. for C₂₆H₂₅N₅O₅ : C, 64.06; H, 5.17; N, 14.37 %).

1-Diethylaminomethyl-3-[4'-(4''-nitrobenzyloxy)-benzoylhydrazono]-5-methylindolin-2-one, 17

Yield 48 %, m.p.180⁰C; IR (cm⁻¹): 3433 (NH), 2830 (>N-CH₂-N<), 1692 (CO), 1523, 1345 (NO₂), 1258 (-CH₂O-); ¹H NMR (CDCl₃): 1.87-2.09 (6H, t, CH₂Me), 2.19-2.28 (4H, q, CH₂Me), 2.56 (3H, s, ArMe), 4.47 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.00-8.29 (10H, m, Ar-H), 13.98 (1H, s, CONH); MS m/z: 515 (M⁺). (Found: C, 63.15; H, 5.76; N, 13.50. Calcd. for C₂₈H₂₉N₅O₅ : C, 63.23; H, 5.67; N, 13.58 %).



(i) 4-Nitrobenzyl bromide

K₂CO₃(anhyd); Me₂CO

(ii) N₂H₄.H₂O; 1-Propanol

(iii) 5-Methylindolin-2,3-diones,
gl. AcOH; EtOH

(iv) Amines,CH₂O; DMF

R = H, Me, Et, Bz, COCH₃, CH₂OH

R' = morpholino, piperidino, pyrrolidino

N-methylpiperazino, N-ethylpiperazino,

N-phenylpiperazino, N-benzylpiperazino,
dimethylamino,diethylamino

Scheme I

Acknowledgement

Authors are thankful to Prof (Dr.) R. R. Lyall, Manager and Prof. (Dr.) Mukesh Pati, Principal, LCPGC, Lucknow for providing laboratory facilities and encouragement and Director, C.D.R.I. for IR, ¹H NMR and elemental analysis.

References

1. M. Imran, O. Alam, D. Kaushik and S. A. Khan, *Indian J. Heterocyclic Chem.*, 2007; **16**, 251.
2. T. Aboul-Fadl, M. K. Abdel-Hamid and A. F. Youssef, *Der Pharma Chemica*, 2015; **7**, 217.
3. A. T. Taher, N. A. Khalil and E. M. Ahmed, *Arch. Pharm. Res.*, 2011; **4**, 1615.
4. H. Ramadoss, D. Saravanan, S. P. N. Sudhan and S. S. Mansoor, *Der Pharma Chemica*, 2016; **8**, 94.
5. P. S. Bhasin, N. Sachdeva, S. N. Pandeya, G. Nath and S. K. Singh, *Acta Pharmaceutica Turcica*, 2005; **47**, 21.
6. R. K. Tiwari, N. Rastogi, R. Sethi and S. Shukla, *J. Indian Chem. Soc.*, 2008; **85**, 85
7. K. C. Joshi, R. Jain, P. Chand and S. Garg, *J. Indian Chem. Soc.*, 1983; **60**, 760.
8. S. Suresh, K. B. Priyanka, P. Maharaj, Ch. Srikanth, K. Karthik and G. Sammaiah, *Asian J. Pharma.Clinical Res.*, 2013; **1**, 65.
9. K. Swathi and M. Sarangapani, *World J. Pharmacy Pharma. Sci.*, 2014; **3**, 2070.
10. S. Noshi, K. Zaigham, K. A. Shahzad and T. M. Rana, *Biomedical Lett.*, 2016; **2**, 49.
11. S. Tiwari, *Int. J. Chem. Pharma. Sci.*, 2014; **2**, 1225.
12. D. K. Chaudhary, S. Ahmad, S. Maity and M. S. Alam, *Der Pharmacia Lett.*, 2013; **5**, 285.
13. V. Raj, *Int. J. Current Pharma. Res.*, 2012; **4**, 1.
14. M. Verma, S. N. Pandeya, K. N. Singh and J. P. Stables, *Acta Pharm.*, 2004; **54**, 49.
15. M. Pal, N. K. Sharma, Priyanka and K. K. Jha, *J. Adv. Sci. Res.*, 2011; **2**, 35.
16. B. Bhriugu, D. Pathak, N. Siddiqui, M. S. Alam and W. Ahsan, *Int. J. Pharma. Sci. Drug. Res.*, 2010; **2**, 229.
17. N. D. Wakchaure, S.S. Shejwal, V. K. Deshmukh and S. R. Chaudhari, *Am. J. PharmTech Res.*, 2012; **2**, 288.
18. T. Aboul-Fadl and F. A. S. Bin-Jubair, *Int. J. Res. Pharm. Sci.*, 2010; **1**, 113.

19. C. R. Prakesh, T. Anusha, P. Ashok, K. Rajasekhar, U. Pavankumar, P. Jayaraju and B. S. Rao, *Int. J. Health Pharm. Sci.*, 2012; **1**, 5.
20. M. Asif, *Universal J. Chem.*, 2016; **1**, 29.
21. P. Phogat and P. Singh, *Central Nervous System Agents Med. Chem.*, 2015; **15**, 28.
22. R. Hajare, S. Kulkarni, M. Thakar and R. Paranjape. *World J. Pharamcy Pharma. Sci*, 2016; **5**, 569.
23. S. N. Pandeya, S. Smitha, M. Jyoti and S. K. Sridhar, *Acta Pharm*, 2005; **55**, 27.
24. A. Singh, *Int. J. Pharma. Res.*, 2014; **6**, 1.
25. B. V. Silva, *J. Braz. Chem. Soc.*, 2013; **24**, 707.
26. C. N. Nalini, S. R. Deepthi, N. Ramalakshmi and G. Uma, *Rasayan J. Chem.*, 2011; **4**, 829.
27. D. A. Harrison, N. Rastogi and M. Rahman, *Indian J. Heterocyclic Chem.*, 2013; **23**, 21.
28. N. Rastogi and D. A. Harrison, *J. Indian Chem. Soc.*, 2012; **89**, 1543.
29. P. Kant, D. K. Lohiya and N. Rastogi, *Indian J. Heterocyclic Chem.*, 2015; **24**, 363.
30. N. Rastogi, *Indian J. Heterocyclic Chem.*, 2015; **25**, 65.
31. M. L. Dhar, M. M. Dhar, B. N. Dhawan, B. N. Mehrotra and C. Ray, *Indian J. Exp. Biol.*, 1968; **6**, 232.
32. Z. K. Khan, "In vitro and in vivo screening techniques for antibacterial and antifungal activity in Medicinal Plants, their bioactivity, screening and evaluation", Proceedings Int. workshop UNIDO-CDRI, 1997, pp 210-211.